AIM:DNL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Diurnal Group plc operates as a specialty pharma company worldwide. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Diurnal Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DNL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.3%

DNL

-2.1%

GB Biotechs

1.2%

GB Market


1 Year Return

82.8%

DNL

35.5%

GB Biotechs

-13.2%

GB Market

Return vs Industry: DNL exceeded the UK Biotechs industry which returned 35.7% over the past year.

Return vs Market: DNL exceeded the UK Market which returned -12.7% over the past year.


Shareholder returns

DNLIndustryMarket
7 Day7.3%-2.1%1.2%
30 Day4.5%1.0%-0.2%
90 Day62.5%10.1%-1.1%
1 Year82.8%82.8%36.5%35.5%-9.8%-13.2%
3 Year-56.2%-56.2%-2.0%-3.3%-3.4%-15.1%
5 Yearn/a25.2%22.6%25.3%-2.7%

Price Volatility Vs. Market

How volatile is Diurnal Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Diurnal Group undervalued compared to its fair value and its price relative to the market?

3.87x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DNL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate DNL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DNL is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: DNL is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DNL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DNL is good value based on its PB Ratio (3.9x) compared to the GB Biotechs industry average (5.1x).


Next Steps

Future Growth

How is Diurnal Group forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

25.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DNL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DNL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DNL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DNL's revenue (46.5% per year) is forecast to grow faster than the UK market (6.2% per year).

High Growth Revenue: DNL's revenue (46.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DNL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Diurnal Group performed over the past 5 years?

-11.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DNL is currently unprofitable.

Growing Profit Margin: DNL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DNL is unprofitable, and losses have increased over the past 5 years at a rate of 11.6% per year.

Accelerating Growth: Unable to compare DNL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DNL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.1%).


Return on Equity

High ROE: DNL has a negative Return on Equity (-22.15%), as it is currently unprofitable.


Next Steps

Financial Health

How is Diurnal Group's financial position?


Financial Position Analysis

Short Term Liabilities: DNL's short term assets (£19.2M) exceed its short term liabilities (£2.6M).

Long Term Liabilities: DNL's short term assets (£19.2M) exceed its long term liabilities (£36.0K).


Debt to Equity History and Analysis

Debt Level: DNL is debt free.

Reducing Debt: DNL has no debt compared to 5 years ago when its debt to equity ratio was 1.4%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DNL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: DNL has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 15.5% each year


Next Steps

Dividend

What is Diurnal Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DNL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DNL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DNL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DNL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DNL's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average board tenure


CEO

Martin Whitaker

no data

Tenure

UK£324,000

Compensation

Dr. Martin Whitaker, BSc, Ph.D., serves as the Chief Executive Officer and Executive Director of Diurnal Group Plc since December 1, 2015. Dr. Whitaker serves as an Operations Director of Critical Pharmace ...


CEO Compensation Analysis

Compensation vs Market: Martin's total compensation ($USD419.75K) is about average for companies of similar size in the UK market ($USD345.93K).

Compensation vs Earnings: Martin's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Martin Whitaker
CEO & Executive Directorno dataUK£324.00k0.48%
£ 340.8k
Richard Bungay
CFO, Director & Company Secretary3.67yrsUK£275.00k0.088%
£ 62.7k
Richard Ross
Chief Scientific Officer & Executive Director4.75yrsUK£18.00k1.81%
£ 1.3m
Alan Raymond
Non-Executive Director4.75yrsUK£29.00k0.055%
£ 39.1k
John Goddard
Independent Non-Executive Director4.75yrsUK£30.00k0.16%
£ 117.1k
Samuel Williams
Interim Chairman0.25yrUK£29.00k0.070%
£ 49.9k

4.8yrs

Average Tenure

51yo

Average Age

Experienced Board: DNL's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: DNL insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44.2%.


Top Shareholders

Company Information

Diurnal Group plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Diurnal Group plc
  • Ticker: DNL
  • Exchange: AIM
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£71.380m
  • Shares outstanding: 122.02m
  • Website: https://www.diurnal.co.uk

Number of Employees


Location

  • Diurnal Group plc
  • Cardiff MediCentre
  • Heath Park
  • Cardiff
  • South Glamorgan
  • CF14 4UJ
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DNLAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPDec 2015
4UUDB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2015

Biography

Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, ad ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/18 02:53
End of Day Share Price2020/09/17 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.